stockrowImmunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) Free cash flow
Immunome, Inc.'s free cash flow for fiscal 2025 was −$200.6M, compared with −$118.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$219.1M. Over the past ten years it has ranged from −$200.6M (fiscal 2025) to −$7.6M (fiscal 2018) — the current reading is the lowest in ten years. Immunome, Inc. ranks 547th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$200.6M | — |
| FY2024 | −$118.0M | — |
| FY2023 | −$8.4M | — |
| FY2022 | −$28.9M | — |
| FY2021 | −$18.3M | — |
| FY2020 | −$12.7M | — |
| FY2019 | −$9.8M | — |
| FY2018 | −$7.6M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$63.9M | — |
| Mar 2026 | −$61.6M | — |
| Dec 2025 | −$52.0M | — |
| Sep 2025 | −$41.6M | — |
| 25 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.0M |
| ADMA ADMA Biologics Inc compare | $140.5M |
| VCEL Vericel Corporation compare | $57.9M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| IMNM Immunome, Inc. | −$219.1M |
| CLDX Celldex Therapeutics, Inc. compare | −$242.1M |
| VERA Vera Therapeutics, Inc. compare | −$338.9M |
| BHVN Biohaven Ltd. compare | −$473.2M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$524.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement